ANAPTYSBIO, INC (ANAB) research
ANAPTYSBIO, INC- Sector
- Biotechnology
- Last price
- $48.53
- As of
ANAPTYSBIO, INC (ANAB): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
As of . Source: SEC EDGAR filings for ANAB. Method and limitations.
Share the ANAB intelligence card
See the full ANAB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANAB on one page. Preview it with sample data, then open it live with a free account.
Preview the ANAB dossierActive signals for ANAB
- lowEARNINGS_BEAT
Q2-2026: EPS $5.11 vs $0.0031 estimate, +5.11 on a near-zero consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 97% of ANAB (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +70% to ANAB (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 65% of ANAB (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 72% of ANAB (2026Q2)
FREE, NO ACCOUNT
Every signal on ANAB, as it fires
You are seeing 5 of 13 signals recorded on ANAB since 2026-05-17.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANAB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 032724106 · 2026Q2 | $54.5M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 032724106 · 2026Q2 | $36.4M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 032724106 · 2026Q2 | $26.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 032724106 · 2026Q2 | $17.8M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 032724106 · 2026Q2 | $3.9M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANAB
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANAB against its peers
ANAB's operating margin of 20.4% ranks in the 96th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ANAB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 235M USD | 118M USD | 77 | 10 |
| Operating margin | 20.4% | -158.4% | 96 | 11 |
| Net margin | -5.6% | -165.6% | 88 | 11 |
| Return on equity | -35.6% | -50.2% | 71 | 18 |
Peers (20): AVBP, MAZE, TYRA, INBX, IMCR, SNDX, RARE, NTLA, RAPP, GHRS, DRTS, TSHA, ABSI, FBRX, ORIC, STOK, NBTX, IMTX, DMRA, VIR. Left out: KLRA (no annual filing), COAG (no annual filing), KALV (no annual filing), AAPG (period gap), KARD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANAB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ANAB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ANABand get the insider, 13F, options, and confluence read in one view.